Ward M K, Fraser T R
Br Med J. 1974 Jul 13;3(5923):86-9. doi: 10.1136/bmj.3.5923.86.
In 11 patients with vasopressin-sensitive diabetes insipidus the effectiveness of the vasopressin analogue 1-desamino-8-D-arginine vasopressin (DDAVP) for controlling diabetes insipidus has been compared with that of lysine vasopressin. DDAVP in equivalent intravenous dosage has been found to be at least as potent and to have a more prolonged action, lasting 13-22 hours instead of 1-2 hours. Twice-daily intranasal DDAVP effected satisfactory control in all these patients, without side effects, and all the patients preferred this to their previous treatment. Single daily intramuscular injections of DDAVP were found to offer excellent control for any subject unable to manage intranasal administration.
在11例血管加压素敏感性尿崩症患者中，比较了血管加压素类似物1-去氨基-8-D-精氨酸血管加压素（DDAVP）与赖氨酸血管加压素控制尿崩症的效果。已发现等量静脉注射剂量的DDAVP效力至少相同且作用更持久，持续13 - 22小时而非1 - 2小时。每日两次经鼻给予DDAVP可使所有这些患者获得满意控制，且无副作用，所有患者都更喜欢这种治疗方式而非他们之前的治疗。对于任何无法进行经鼻给药的患者，发现每日单次肌肉注射DDAVP可实现极佳的控制效果。
